{"id":390767,"date":"2017-12-19T00:00:00","date_gmt":"2017-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0016-2017-biopharma-rheumatoid-arthritis-access-and-reimbursement-eu5-2017\/"},"modified":"2026-03-31T10:49:05","modified_gmt":"2026-03-31T10:49:05","slug":"acreim0016-2017-biopharma-rheumatoid-arthritis-access-and-reimbursement-eu5-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0016-2017-biopharma-rheumatoid-arthritis-access-and-reimbursement-eu5-2017\/","title":{"rendered":"Rheumatoid Arthritis | Access and Reimbursement | EU5 | 2017"},"content":{"rendered":"<p>The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (TNF)-\u03b1 inhibitors and four biologics with alternative mechanisms of action. The TNF-\u03b1 inhibitors are the most widely prescribed biologics in RA patients refractory to conventional DMARDs, and the non-TNF-\u03b1 biologics largely compete for use in TNF-refractory patients. However, the premium-priced branded TNF-\u03b1 inhibitors face a competitive threat from the recent launch of biosimilars, including biosimilar infliximab and biosimilar etanercept, which provide cost-effective alternatives. In addition, Jak inhibitors Xeljanz (Pfizer\u2019s tofacitinib) and Olumiant (Eli Lily\/Incyte\u2019s baricitinib) received EC marketing authorization for use in RA in the first quarter of 2017. With the impending entry of additional IL-6 inhibitors and Jak inhibitors, and biosimilars of several other TNF and non-TNF biologics, marketers are faced with fierce competition as EU5 payers and prescribers balance clinical need with budgetary constraints.<\/p>\n<p>Questions Answered:<\/p>\n<ul>\n<li>\u00a0What clinical and cost-related factors most strongly influence and restrict prescribing of key RA therapies? How do these differ across the EU5?<\/li>\n<li>What factors will determine the success of recently approved and emerging Jak and IL-6 inhibitors, including Sanofi\/Regeneron\u2019s sarilumab and Janssen\u2019s sirukumab? How do payers intend to reimburse emerging agents? To what extent will payer policy impact prescribing of them?<\/li>\n<li>What can manufacturers do to achieve favorable pricing and reimbursement terms, maximize uptake and, therefore, optimize market access?<\/li>\n<\/ul>\n<p>Scope:<\/p>\n<ul>\n<li><strong>Markets covered: <\/strong>France, Germany, Italy, Spain, United Kingdom.<\/li>\n<li><strong>Methodology:<\/strong> Surveys of 252\u00a0dermatologists and 10 country-specific interviews with European payers.<\/li>\n<li><strong>Indication coverage:<\/strong>\u00a0Rheumatoid arthritis.<\/li>\n<li><strong>Key drugs covered: <\/strong>Enbrel, Humira, Remicade, Simponi, Cimzia, Orencia, RoActemra, MabThera, Xeljanz, Olumiant, Inflectra, Remsima, Flixabi, Benepali, Truxima, Amgevita, sarilumab, sirukumab, ABT-494.<\/li>\n<li><strong>Key companies mentioned<\/strong>: Pfizer, Merck, AbbVie, UCB, Roche, Bristol-Myers Squibb, Janssen, Eli Lilly, Sanofi, Regeneron, Hospira, Celltrion, Biogen.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390767","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390767\/revisions"}],"predecessor-version":[{"id":393891,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390767\/revisions\/393891"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}